Results 281 to 290 of about 275,378 (374)

Efficacy of glucocorticoids treatment in recurrent embryo implantation failure. [PDF]

open access: yesCell Death Discov
Cai QY   +7 more
europepmc   +1 more source

Complications associated with subpalpebral lavage systems in upper and lower equine eyelids: A prospective, randomised study in 73 cases (2015–2024)

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Evidence for optimal location of subpalpebral lavage (SPL) systems is lacking. Objectives To compare the rate and types of complications with SPL systems located in central upper‐ compared with medial lower‐eyelid in hospitalised patients. Study Design Prospective, randomised treatment trial.
Annabelle E. Graham   +2 more
wiley   +1 more source

Can atogepant be a preventive treatment for cluster headache?—Insights from a case series

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Cluster headache (CH) is a disabling primary headache disorder with limited therapeutic options. Calcitonin gene‐related peptide (CGRP) is known to be involved in CH pathophysiology; however, except for galcanezumab (300 mg) in episodic CH, anti‐CGRP monoclonal antibodies did not reduce CH attacks in randomized clinical trials. Atogepant is an
Catarina Serrão   +3 more
wiley   +1 more source

A case of propylthiouracil induced antineutrophil cytoplasmic antibody associated vasculopathy

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nikhil Dwivedi   +2 more
wiley   +1 more source

Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low‐grade immune‐related adverse events (irAEs) are associated with prolonged survival, high‐grade irAEs have been associated with poorer survival. Cutaneous immune‐related adverse events (cirAEs) affect up to 20%
David O'Reilly   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy